Centene Corp. Stock

Centene’s fiscal 2025 results present a jarring contrast: total revenue expanded by nearly one‑fifth to just under $195 billion, yet the company recorded a net loss of $6.7 billion. The loss stems from a non‑cash impairment charge of over $7 billion, without which operating income would have been close to break‑even. Equity contracted by roughly a quarter, while the business continued to add members across its government‑sponsored health plans.

Revenue growth was led by the Medicare and Commercial segments, where premiums surged, whereas the core Medicaid book grew more modestly. Beneath the top line, however, profitability crushed. Operating margins turned sharply negative, and the medical loss ratio – the share of premiums consumed by medical claims – climbed meaningfully in both the Medicare and Commercial lines. This suggests that the rapid enrollment gains may be accompanied by cost pressures or less favorable risk selection. The reported gross margin of roughly 98.6% is an accounting construct that excludes medical costs; the economic margin after claims is much thinner and became negative in the period.

The balance sheet reveals the depth of the impairment. Goodwill fell by $6.7 billion, nearly all of it within the Medicaid reporting unit, whose goodwill shrank from $10.2 billion to $4 billion. Intangible assets also declined moderately. Despite the equity hit, the company retains a net cash position—cash and short‑term investments comfortably exceed total debt—and the debt‑to‑equity ratio of 0.87, though higher than last year, still appears manageable. Current liquidity, with a quick ratio near 1.1, is adequate though not ample, and medical claims liabilities rose to $20.5 billion, mirroring the membership growth and possibly higher utilization.